Despite that extracellular vesicles are ideal to be used as drug carriers,24,26,28 how to use these natural biomaterials for cancer immunotherapy remains largely to be explored.48,49 In this study, we provide evidence that drug-MPs reset M2 macrophages to M1 by activating lysosomal cytochrome P450 and nuclear hnRNPA2B1 (Fig. 8), thus facilitating the neutrophil recruitment24,28 and enhancement of antitumor immunity. Here, HNRNPA2B1 is linked to cancer.